12:00 AM
Nov 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Effient prasugrel: Phase II data

Data from the double-blind, crossover Phase II OPTIMUS-3 trial in 35 patients with Type II diabetes and CAD who were also taking aspirin showed that Effient significantly increased IPA vs. Plavix clopidogrel at 4 hours post-loading dose (89% vs. 28%, p<0.0001), 1 hour post-loading dose (50% vs. 13%, p<0.0001), 24 hours post-loading dose (87%...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >